StreetInsider.com News Articles

Elanco Animal Health Appoints Jamie Preston as Chief People Officer

Thu, 22 Oct 2026 06:53:00 -0400

Preston brings more than two decades of global HR leadership and workforce innovation experience; Dave Kinard to retire at year-end

INDIANAPOLIS, Oct. 22, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Jamie Preston as Executive Vice President and Chief People Officer, effective November 3^rd. Preston's appointment follows an extensive

Elanco Animal Health Appoints Jamie Preston as Chief People Officer

Thu, 22 Oct 2026 06:53:00 -0400

Preston brings more than two decades of global HR leadership and workforce innovation experience; Dave Kinard to retire at year-end

Form 4 Elanco Animal Health For: Oct 16 Filed by: Modi Rajeev A.

Tue, 20 Oct 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20261020/27210749.html

Form 4 Elanco Animal Health For: Oct 16 Filed by: Simmons Jeffrey N

Tue, 20 Oct 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20261020/27210744.html

Form 4 Elanco Animal Health For: Oct 16 Filed by: VanHimbergen Robert M

Tue, 20 Oct 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20261020/27210741.html

Jefferies downgrades Zoetis, Elanco on pricing risk; prefers IDEXX

Tue, 20 Oct 2026 08:43:45 -0400

Investing.com -- Jefferies downgraded Zoetis and Elanco to Hold from Buy on Tuesday, warning that pricing power in animal health is at risk. The firm reiterated its Buy rating on IDEXX Laboratories.

“Pricing power is at risk in animal health, but diagnostics isn’t like the rest of the industry,” analyst Keith Devas wrote.

Jefferies noted that price and mix now account for all growth in vet and pet services, compared with 50% to 65% before the pandemic.

With muted vet visits, mid-single-digit vet labor inflation and waning owner sentiment, the firm said assuming continued pricing gains for the industry is a

Jefferies downgrades Zoetis, Elanco on pricing risk; prefers IDEXX

Tue, 20 Oct 2026 08:43:45 -0400

Investing.com -- Jefferies downgraded Zoetis and Elanco to Hold from Buy on Tuesday, warning that pricing power in animal health is at risk. The firm reiterated its Buy rating on IDEXX Laboratories.

“Pricing power is at risk in animal health, but diagnostics isn’t like the rest of the industry,” analyst Keith Devas wrote.

Jefferies noted that price and mix now account for all growth in vet and pet services, compared with 50% to 65% before the pandemic.

With muted vet visits, mid-single-digit vet labor inflation and waning owner sentiment, the firm said assuming continued pricing gains for the industry is a

Jefferies downgrades Zoetis, Elanco on pricing risk; prefers IDEXX

Tue, 20 Oct 2026 08:43:45 -0400

Investing.com -- Jefferies downgraded Zoetis and Elanco to Hold from Buy on Tuesday, warning that pricing power in animal health is at risk. The firm reiterated its Buy rating on IDEXX Laboratories.

“Pricing power is at risk in animal health, but diagnostics isn’t like the rest of the industry,” analyst Keith Devas wrote.

Jefferies noted that price and mix now account for all growth in vet and pet services, compared with 50% to 65% before the pandemic.

With muted vet visits, mid-single-digit vet labor inflation and waning owner sentiment, the firm said assuming continued pricing gains for the industry is a

Jefferies Downgrades Elanco Animal Health (ELAN) to Hold

Tue, 20 Oct 2026 05:10:21 -0400

(Updated - October 20, 2026 5:10 AM EDT)

Jefferies analyst Keith Devas downgraded Elanco Animal Health (NYSE: ELAN) from Buy to Hold, PT $24.00 (from $31.0.0).

The analyst comments "Volume, not price, has driven a growth transformation, and trends are holding in '26. But Zoetis' concessions add risk to the path ahead. Our base case assumes 4% growth from '26-'28 as less help from pricing delivers 8% EPS CAGR vs. LDD% target. Shares rerated over the past year to reflect the inflection, so upside needs better numbers, which carries risk. Our $24 PT is based on 18x '28 EPS of $1.32."

For an

Jefferies Downgrades Elanco Animal Health (ELAN) to Hold

Tue, 20 Oct 2026 05:10:21 -0400

(Updated - October 20, 2026 5:10 AM EDT)

Jefferies analyst Keith Devas downgraded Elanco Animal Health (NYSE: ELAN) from Buy to Hold, PT $24.00 (from $31.0.0).

For an

Jefferies Downgrades Zoetis Inc. (ZTS) to Hold

Tue, 20 Oct 2026 05:09:50 -0400